Eversight, a nonprofit eye bank, announced the availability of Descemet’s membrane endothelial keratoplasty (DMEK) tissue preloaded in EndoGlide, which offers corneal surgeons an additional preloaded DMEK option, making it the fourth one, that helps in making the surgery more efficient and cost-effective.
The Preloaded DMEK EndoGlide makes use of an endothelium-in or trifold loading method, unlike traditional injectable DMEK grafts, which are loaded endothelium-out. The graft is infused into the eye with the help of an anterior chamber maintainer and is then pulled into the eye with specialized forceps through a 2.65mm incision. Due to its endothelium-in loading method, the DMEK graft naturally tends to unscroll in the correct orientation.
According to EverSight, the preloaded DMEK EndoGlide offers added control over the graft and its orientation through the pull-through technique and the endothelium-in attribute. This is crucial for the success of the procedure and may even make DMEK possible in more complex eyes.
“DMEK provides favorable clinical outcomes for patients and is an efficient use of surgeon time and healthcare resources,” Michael Titus, Vice President of Clinical Operations, Eversight, said in a company news release. “As adoption of DMEK continues to grow, we listened to surgeons who aim to make the procedure available to more of their patients. Eversight is dedicated to providing improved tissue preparation services like preloaded DMEK EndoGlide that can ultimately improve access to quality eye care.”
To learn more about DMEK in EndoGlide and access free on-demand training to adopt this surgical technique, click here.